Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: A cell cultivation apparatus for cultivating microorganisms and growing cells at high density is provided. The apparatus includes a membrane comprising multiple surface features on a first side of the membrane for cell placement. The surface features comprising one or more compartments within which a cell can be located. The membrane includes a material that is at least partially permeable to gas. A second side of the membrane defines a gas region. The second side of the membrane is separated from the first side of the membrane by the membrane. The apparatus further includes a media region for receiving media. The compartments are configured to at least partially reduce media flow shear forces on one or more cells in the compartments. The surface features may be ridges, protrusions, fins, wells, and/or posts.

Abstract: A wheel measurement system includes a wheel position and orientation system (WPOS) that has a linear sensor configured to connect with a vehicle and extend between a body of the vehicle and a wheel of the vehicle to measure linear motion therebetween while the vehicle is in motion and two or more rotary sensors configured to monitor angular changes at a mounting position of the linear sensor at the body of the vehicle and a mounting position of the linear sensor at the wheel of the vehicle while the vehicle is in motion. The linear motion and the angular changes determine movements of the wheel relative to the body while the vehicle is in motion.

Abstract: The system and method forecast the future success of a company and/or product based upon historical popularity and performance data. The system and method analyze, score, and rank a company or product based upon how likely it is to succeed based historical and current popularity, consumer sentiment, sales, trend, ethicality, and financial health data. A computer-implemented method for swapping a selected product for a product having a higher attribute, or sustainability score analyzes the selected product to determine its score, finds products that are similar to the selected product, determines a sustainability score for each similar product, then ranks the similar products by similarity and corresponding sustainability score. One of the highest ranked similar products can then be swapped for the selected product if its sustainability score is higher than the sustainability score of the selected product.

Abstract: A cell cultivation apparatus for cultivating microorganisms and growing cells at high density is provided. The apparatus includes a membrane comprising multiple surface features on a first side of the membrane for cell placement. The surface features comprising one or more compartments within which a cell can be located. The membrane includes a material that is at least partially permeable to gas. A second side of the membrane defines a gas region. The second side of the membrane is separated from the first side of the membrane by the membrane. The apparatus further includes a media region for receiving media. The compartments are configured to at least partially reduce media flow shear forces on one or more cells in the compartments. The surface features may be ridges, protrusions, fins, wells, and/or posts.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Abstract: According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.

Abstract: According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Abstract: The present application describes an integrated module. The integrated module includes a microcontroller, an inertial measurement unit (IMU), a low-power accelerometer, and an environmental sensor. A noise target between the IMU and low-power accelerometer is less than a noise target be the IMU and microcontroller. The present application also describes a method of using an integrated module.

Abstract: A packaging comprising a tray having an opening, a cavity including at least three cavity portions, a plurality of sidewalls, and a base; and a sterile syringe contained within the cavity, wherein the sterile syringe is pre-filled with a medicament or other fluid; wherein a first cavity portion comprises a plunger rod of the sterile syringe, a second cavity portion comprises a barrel of the sterile syringe, and a third cavity portion comprises a needle attachment portion of the sterile syringe, wherein the at least three cavity portions are connected to one another by intermediate narrowed portions, and wherein each of the narrowed portions includes a first sidewall, a second sidewall, a base, and a plurality of geometric features projecting into the narrowed portions to position the sterile syringe away from the plurality of sidewalls.

Abstract: A stator angle is determined to correct a value measured by a wheel force transducer. A mounting bracket is rigidly attached to a vehicle and supports a housing within which a rotary encoder is mounted. A stator rod retainer is aligned with a rotational axis of the rotary encoder and has a through-bore extending perpendicular to the rotational axis. The stator rod retainer rotates relative to a stationary portion of the rotary encoder using at least one bearing, and the stator rod retainer supports a first end of a stator rod for substantially free movement through the through-bore. A controller determines, when the second end of the stator rod is fixedly attached to an encoder stator attached to a wheel, a stator angle of the stator rod used for adjusting at least one value associated with the wheel that is measured using the encoder stator.

Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.